Dr John Best


www.orthosports.com.au

160 Belmore Rd, Randwick



Dr John Best Sport & Exercise Medicine Physician

The Non-Operative Management of Knee Joint Osteoarthritis (KJOA)







KJOA - Prevalence and burden

- Chronic disease joint pain, swelling, altered qOL
- OA sufferers report fair to poor health
 - National Orthopaedic Registry 2016
- 45% lifetime risk; increases >55years
- 65% prevalence with obesity
- X-ray changes in 25% 50yo; 85% >65 yo
- The aim of good non-operative care is to improve qOL and delay arthroplasty



Pathogenesis of KJOA

- Genetics, trauma, malalignment, other.....
- Imbalance between anabolism and catabolism
- Not simply the "wear and tear" of ageing
- Chronic inflammatory changes including the upregulation of substances such as matrix metalloproteinases (MMPs), proliferation of cytokines and inflammatory mediators
- Volume of KJ articular cartilage degenerates by 4-5% / decade; more rapidly with obesity

Load and Knee Joint Mechanics

- Altered load with:
 - Varus / valgus
 - Patella tilting
 - Meniscectomy
- Normal Walking
 - 150% TBW through knees
- Stairs
 - 250% TBW through knees
- Squat
 - 500% TBW through knees







Dr John Best eine Physician

Altered metabolites Altered body composition Synovial Nutrients effusion Lipids 1 Glucose 1 Body Eroded Thickened measures cartilage capsule BMI ↑ Hormones Waist/Hip Osteophyte Narrowed Estrogen J Ratio 1 Testosterone 1 joint space Body fat ↑ Vitamin D Inflamed Lean mass . Muscle synovium Subchondral strength 1 Others bone lesion Nitric oxide † Reactive oxygen Metabolic inflammation triggered species 1 osteoarthritic damage

Synovium and chondrocyte-derived inflammatory mediators



IL-1, IL-8, IL-18, IL-6 ... 1 TNF-a, LIF ↑ Chemokines 1 IL-10, IL-4 ... J

MicroRNAs

miR-9, 16, 22, 103, 138, 222, 377 ... 1 miR-26, 29a, 95, 140, 146a, 221, 337 ... J

Acute-phase components

CRP1 C3, C5 ↑ MAC 1

Adipose tissue-derived inflammatory mediators

Adipokines

Leptin ↑ Resistin 1 Visfatin ... 1 Adiponectin !



Principles of Non-Operative Management of KJOA

Lifestyle Factors	Chemical Factors
Weight Management	Analgesia/ Inflammation – oral/ topical
Load Management	Non-prescription meds; supplements
Exercise and Rehabilitation	Analgesia/ Inflammation - injections
Eating patterns and diet	Injections to improve loading
Psychological and behavioural factors	Injections claiming to offer regeneration



1 Diagnosis, grading and individualised management

- qOL = night pain, mobility, ADLs, squat ability
- Activity background, expectations, treatments
- Introduce concept of a 'journey' management pathway, using understandable language
- Functional assessment
 - 6min walk test or 4 x 10m walks
 - 30 sec 'sit to stand'; stair climb test
 - OARSI (2013) Dobson et al



2 Manage Pain and Inflammation well

- Load management and analgesia
 - Ice; paracetamol; topical therapies
- Anti-inflammatories
 - Oral NSAIDs short-term, idiosyncratic, sideeffects
 - Injectable cortisone for synovitis (short term)
 - 70% patients have relief for 3-12 weeks
- Supplements non-TGA assessed
 - Omega 3 FA (eg Fish Oil) varied quality and dose
- Platelet Rich Plasma (PRP) ??

PRP and KJOA (Dr P Annett)

- Research unclear
- In those with a benefit most likely down regulation/modulation of inflammation
- Platelets are a rich source of bioactive molecules; 1100 different proteins
- Does not produce chondrocyte proliferation
- No evidence for slowing disease progression
- No clear protocol








Evidence for PRP Joint

- Knee joint Osteoarthritis
 - Patel 2013. AmJSM
- 156 knees
- 52 PRP, 50 X2 PRP, 46 Saline
- Significant improvement in first 2 groups from 2-3/52 to 6/12
- No difference between 1 & 2 PRP injections
- NS deteriorated

Efficacy of platelet-rich plasma injections in osteoarthritis of the knee: a systematic review and meta-analysis

Augustinus B M Laudy, ^{1,2} Eric W P Bakker, ² Mark Rekers, ³ Maarten H Moen^{4,5}







3 Eating Patterns and Weight Management

- Weight and composition
 - Abdominal fat (peri-organ)
- BMI using ht /wt

Class	BMI range
Underweight	<18.5
Normal /healthy	18.5-25
Overweight	25-30
Obesity Class I	30-35
Obesity Class V	50-60

Overweight and obese patients have accelerating

- Eating Patterns
 - Self control
 - Effects on hormones
- Diet and inflammation
 - Insulin resistance
 - High carbs and Omega 6
- Weight gain and load
- Part of an unhealthy lifestyle including 'comfort eating'

Dr John Best Sport & Exercise Medicine Physician

I/I A

Weight Loss, Diet and Exercise IDEA trial JAMA 2013, Messier et al


- Single blind, 18 month trial
- 2006-2011
- 454 overweight and obese
- Age >55; BMI 27-41, KJOA
- Interleukin -6 levels
- WOMAC scores
- Multiple other tests

 Findings – weight loss through diet and exercise gave superior results. SPECTACULAR

	Changes	in Weight	and BMI
Weight reduction	5-10%	10-20%	>20%
Pain reduction	15-25%	25-50%	>50%
Mobility	+	++	+++



IDEA trial JAMA 2013, Messier et al





4 Manage Load and Exercise Safely

- pain reduction, better sleep and reduced inflammation
- Slower warm up
- Pursue the components of good health and manage load well (EULAR paper 2018, ACSEM recommendations)
- Cardiovascular exercise
 - > 150mins / week; HIIT training options
- Resistance training
 - Major groups, 2-3/week, 2-4 sets, 8-12 reps
 - Novice or >65yrs 35%1RM; Experienced 75% 1RM
- Balance and Flexibility

20-30 min, 2-3/week, Tai Chi, one legged standing John Best Sport & Exercise Medicine Physician

4 Manage Load and Exercise Safely

- pain reduction, better sleep and reduced inflammation
- Load Management
 - Stick; braces; wedges
- Assessing reaction to activity
 - No sharp pain
 - Minimal after-pain / swelling
- Alternate activities avoid lunges
 - Reduced impact
 - Walk, cycle, elliptical, aquatic, doubles and table tennis, boxing, dance, gardening...
 - Variety of positions
- Review as symptoms improve

Enjoy with others; active holidays





Dr John Best Sport & Exercise Medicine Physician

Use of Visco-supplementation HA = Hyaluronic Acid

- High MWt solutions supplement the reduced hyaluronate concentrations
- KJOA synovial fluid exhibits very low HA levels
- Animal, synthetic or microbiological
- Bolus or regime of 3 injections
- Effects to increase load-bearing ability:
 - Physical, Anti-Inflammatory, Anabolic,
 Analgesic, chondroprotective



Results No independent research TGA approved

- Leighton et al Rheumatology : Research Reviews 2018
- Early to moderate OA do better
- 75% who improve have a better follow up injection
- Delayed time to primary surgery

Relationship between x-ray grade and overall response

	Medical x-ray grade	Number of Knees	% Better or Much Better
	I	68	91%
	II	138	80%
	III	180	76%
	IV	57	58%
	Sport & Ex	ercise Med	Dr John Bes icine Physiciai

5 Perform Key Exercises (20mins, 3/week)

- Strength
 - Quads, gluteals
 - Co-contractions



- **Flexibility**
 - Quads, hamstring, hip flexor, ITB





Control

trunk









Dr John Best cine Physician




Sport &

6 Review and Pursue Behaviour Change

- KJOA may control a patient's life
- Psychological and personality factors important
- 'Booster strategies' follow-up calls, emails accountability and compliance
- Biometric monitoring effective in most patients
- Opportunities for change









Gender	male	
Height	178 cm	
Weight	78.5 kg	





7 Keep Up To Date with Research

- Understanding of obesity and diet modulated inflammation
- Finding ways to keep patients active
- Improving subchondral bone
- Looking at regenerative therapies
 - Stem Cells?



Journal of Pathology

| Pathol 2009; 217: 318-324

Published online 16 October 2008 in Wiley InterScience (www.interscience.wiley.com) **DOI**: 10.1002/path.2469

Invited Review

Why are MSCs therapeutic? New data: new insight

Al Caplan*

Skeletal Research Center, Department of Biology, Case Western Reserve University, Cleveland, OH 44106, USA

*Correspondence to: Al Caplan, Skeletal Research Center, Department of Biology, Case Western Reserve University, Cleveland, OH 44106, USA. E-mail: amold.caplan@case.edu

Conflict of interest statement: my colleagues and I started Osiris Therapeutics Inc. in late 1992. I no longer own stock in Osiris, neither do I have direct contact with the company.

Abstract

Adult marrow-derived mesenchymal stem cells (MSCs) are able to differentiate into bone, cartilage, muscle, marrow stroma, tendon-ligament, fat and other connective tissues. The questions can be asked, what do MSCs do naturally and where is the MSC niche? New insight and clinical experience suggest that MSCs are naturally found as perivascular cells, summarily referred to as pericytes, which are released at sites of injury, where they secrete large quantities of bioactive factors that are both immunomodulatory and trophic. The trophic activity inhibits ischaemia-caused apoptosis and scarring while stimulating angiogenesis and the mitosis of tissue intrinsic progenitor cells. The immunomodulation inhibits lymphocyte surveillance of the injured tissue, thus preventing autoimmunity, and allows allogeneic MSCs to be used in a variety of clinical situations. Thus, a new, enlightened era of experimentation and clinical trials has been initiated with xenogenic and allogeneic MSCs.




What are Mesenchymal Stem Cells?

(Courtesy Dr D Kuah)

 Secretions – major driver of the therapeutic effect

 Mixed cell populations produce a potent mixture of secretions

 Strong evidence- from cell therapy in cartilage injury models in animals



MSCs – 'secretion factories' Fat or bone marrow dervived

Angiogenic Anti-Apoptotic Anti-Scarring



Cartilage regeneration and/or modification of OA disease demonstrated in many animal models

ARTHRITIS & RHEUMATISM Vol. 48, No. 12, December 2003, pp 3464–3474 DOI 10.1002/art.11365 № 2003, American College of Rheumatology

Stem Cell Therapy in a Caprine Model of Osteoarthritis

J. Mary Murphy,1 David J. Fink,1 Ernst B. Hunziker,2 and Frank P. Barry1

Enhanced early chondrogenesis in articular defects following arthroscopic mesenchymal stem cell implantation in an equine model

Markus M. Wilke¹, Daryl V. Nydam², Alan J. Nixon¹.*

Article first published online: 2 APR 2007

DOI: 10.1002/jor.20382

ssue



Journal of Orthopaedic Research

Volume 25, Issue 7, pages 913–925, July 2007

STEM CELLS

TRANSLATIONAL AND CLINICAL RESEARCH


Injectable Mesenchymal Stem Cell Therapy for Large Cartilage Defects—A Porcine Model

KEVIN B.L. LEE, JAMES H.P. HUI, IM CHIM SONG, LENNY ARDANY, ENG HIN LEE

The Department of Orthopaedic Surgery, National University of Singapore, and the Department of Experimental Surgery, Singapore, Republic of Singapore

Dr John Best t & Exercise Medicine Physician Treatment of osteoarthritis with infrapatellar fat pad derived mesenchymal stem cells in Rabbit

F.S. Toghraie a, N. Chenari b, M.A. Gholipour a, Z. Faghih b, S. Torabinejad c, S. Dehghani a, A. Ghaderi b,d.*



Dr John Best

Sport & Exercise Medicine Physician

Regulations and Use

- Differ greatly country to country (and even by state). No TGA approval.
- Differ according to type of stem cells, and degree of manipulation
- Haemopoietic/ bone marrow/fat/blood/ etc
- Research use only ACSEP
- It is an invasive procedure
- Vulnerable patients



Summary

- KJOA can create severe disability with altered qOL
- Better understanding of the pathogenesis has provided options with dietary changes, weight reduction and exercise therapies
- Therapies for articular cartilage 're-growth' remains unclear
- Careful, individual follow-up is best practice



Thank you

